

April 1, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.

Ref: Our letter dated August 12, 2021 regarding merger of subsidiaries with the Company.

We refer to our letter dated August 12, 2021 informing about the approval of the Scheme of Amalgamation by the Board of Director of the Company, providing for the amalgamation of wholly owned subsidiaries of the Company viz., Auronext Pharma Private and Mviyes Pharma Ventures Private Limited with the Company subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).

We would like inform you that since there were other restructuring proposals in discussion, this amalgamation was put on hold and now, the Board of Directors of the Company at its meeting held on April 1, 2023 has decided to proceed with the aforesaid Scheme of Amalgamation.

We enclose herewith the details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular NO.CIR/CFD/CMD/4/2015 dated September 9, 2015 in Annexure-A to this letter.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl: Annexure

AUROBINDO PHARMA LIMITED
www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Sl.No.	Particulars	Description																
1	List of the entities forming part of the amalgamation / merger, details in brief such as size, turnover etc.	<u>i) Transferor Companies</u> a. Auronext Pharma Private Limited ("Auronext") b. Mviyes Pharma Ventures Private Limited ("Mviyes") <u>ii) Transferee Company</u> a. Aurobindo Pharma Limited ("APL") <u>iii)</u> The Scheme of Amalgamation provides for amalgamation of the above Transferor Companies with Aurobindo Pharma Limited (Transferee Company). Both the Transferor Companies are wholly owned subsidiaries of the Transferee Company. <u>iv)</u> Turnover/ Revenue for year/period ended: INR in crores <table><tr><th>Name of the Company</th><th>Year ended 31.03.2021</th><th>Year ended 31.03.2022</th><th>Nine months ended 31.12.2022</th></tr><tr><td>Auronext</td><td>353.57</td><td>Nil</td><td>Nil</td></tr><tr><td>Mviyes</td><td>Nil</td><td>Nil</td><td>Nil</td></tr><tr><td>APL</td><td>15,823.68</td><td>11,287.14</td><td>9,244.84</td></tr></table>	Name of the Company	Year ended 31.03.2021	Year ended 31.03.2022	Nine months ended 31.12.2022	Auronext	353.57	Nil	Nil	Mviyes	Nil	Nil	Nil	APL	15,823.68	11,287.14	9,244.84
Name of the Company	Year ended 31.03.2021	Year ended 31.03.2022	Nine months ended 31.12.2022															
Auronext	353.57	Nil	Nil															
Mviyes	Nil	Nil	Nil															
APL	15,823.68	11,287.14	9,244.84															
2	Whether the transaction would fall within related party transactions? If yes, whether the same is done at 'arm's length'	The Transferor Companies are wholly owned subsidiaries of the Transferee Company. The proposed Scheme of Amalgamation being dealt under the specific sections of the Companies Act, 2013, does not fall within the purview of related party transaction pursuant to the circular NO.30/2014 dated 17 July 2014 issued by the Ministry of Corporate Affairs. Further, being the Scheme of Amalgamation between holding company and its wholly owned subsidiary companies, pursuant to the provisions of Regulations 23(5)(b) of SEBI LODR Regulations, 2015, it is exempt from the relevant provisions of related party transactions under the said SEBI LODR Regulations, 2015 as well as from the provisions of SEBI circular dated 10 March 2017.																
3	Area of business of the entities	The Transferor Companies were and the Transferee Company is engaged in the business of manufacturing of pharmaceutical products.																
4	Rationale for amalgamation / merger	The Transferee Company is holding 100% stake directly in the Transferor Companies. The amalgamation of the Transferor Companies with the Transferee Company would <i>inter-alia</i> have the following benefits:																

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500038 T.S., INDIA Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: info@aurobindo.com Website: www.aurobindo.com

		i. The amalgamation will result in reduction of multiplicity of entities, thereby reducing compliance cost of multiple entities viz., statutory filings, regulatory compliances, labour law/ establishment related compliances. ii. The amalgamation will enable appropriate consolidation of activities of Transferor Companies and Transferee Company with pooling and more efficient utilization of their resources, greater economies of scale, reduction in overheads and other expenses and improvement in various operating parameters. Reduction of administrative responsibilities, multiplicity of records and statutory, legal and regulatory compliance and cost savings through legal entity rationalization
5	In case of cash consideration - amount or otherwise share exchange ratio	Since the Transferor Companies are wholly owned subsidiaries of the Transferee Company, no shares of the Transferee Company shall be allotted under the Scheme of Amalgamation.
6	Brief details of change in shareholding pattern (if any) of listed entity	There would be no change in shareholding pattern of the Transferee Company.